Hepatitis B virus reactivation in a patient with resolved hepatitis B virus infection receiving maintenance rituximab for malignant B-cell lymphoma

Annals of Internal Medicine

Volumn 150, Issue 9, 2009, Pages 655-656

  Koo, Yu Xuan ^a   Tan, Daniel S W ^b   Tan, Iain B ^b   Tao, Miriam ^b   Lim, Soon Thye ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLOPHOSPHAMIDE; DOXORUBICIN; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; PREDNISOLONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

AGED; AMINOTRANSFERASE BLOOD LEVEL; B CELL LYMPHOMA; BILIRUBIN BLOOD LEVEL; CANCER SURGERY; CASE REPORT; CELL INFILTRATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOHISTOCHEMISTRY; LETHARGY; LETTER; LYMPH NODE BIOPSY; MAINTENANCE DRUG DOSE; MALE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; VIRUS REACTIVATION; PHYSIOLOGY; VIROLOGY; VIRUS ACTIVATION;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; VIRUS ACTIVATION;

EID: 65649121196     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-150-9-200905050-00024     Document Type: Letter

References (5)

1. Kahl BS, Longo WL, Eickhoff JC, Zehnder J, Jones C, Blank J, et al; Wisconsin Oncology Network. Maintenance rituximab following induction chemoimmuno- therapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol. 2006;17:1418-23. [PMID: 16766582]
2. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing antican- cer therapy with or without rituximab. J Clin Oncol. 2009;27:605-11. [PMID: 19075267]
3. Koo YX, Tan SW, Tan BH, Quek R, Tao M, Chow WC, et al. Risk of hepatitis B virus (HBV) reactivation and role of anti-viral prophylaxis in lymphoma patients with past HBV infection (HBV antigen negative but anti-hepatitis B core antibody positive) receiving chemo-immunotherapy blood [Abstract]. ASH Annual Meeting Abstracts. 2008;112:3768.
4. Targhetta C, Cabras MG, Mamusa AM, Mascia G, Angelucci E. Hepatitis B virus- related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy [Letter]. Haematologica. 2008;93:951-2. [PMID: 18515881]
5. Sera T, Hiasa Y, Michitaka K, Konishi I, Matsuura K, Tokumoto Y, et al. Anti- HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med. 2006;45:721-4. [PMID: 16819252]